| Safety and Tolerability of AZD5148 in Japanese Participants (NCT06639997) | AstraZeneca | 2024-10-31 |
| A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure (NCT06692764) | AstraZeneca | 2024-10-30 |
| A Phase I PK Study of Balcinrenone/Dapagliflozin in Healthy Chinese Participants (NCT06651021) | AstraZeneca | 2024-10-21 |
| A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation (NCT06599502) | AstraZeneca | 2024-10-18 |
| Establish FeNO Cut-off Value for Predicting Budesonide-formoterol Response in Chronic Cough Suggestive of CVA Patients. (NCT06590740) | AstraZeneca | 2024-10-18 |
| A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer (NCT06340581) | AstraZeneca | 2024-10-17 |
| Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Patients With Crohn's Disease. (NCT06432764) | AstraZeneca | 2024-10-16 |
| A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features (NCT06564844) | AstraZeneca | 2024-10-15 |
| AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal Impairment (NCT06611423) | AstraZeneca | 2024-10-15 |
| Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus. (NCT06579105) | AstraZeneca | 2024-10-08 |
| Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity (NCT06579092) | AstraZeneca | 2024-10-08 |
| A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NCT06417814) | AstraZeneca | 2024-10-04 |
| A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity (NCT06595238) | AstraZeneca | 2024-10-01 |
| Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. (NCT06473779) | AstraZeneca | 2024-09-30 |
| A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs (NCT05663515) | AstraZeneca | 2024-09-30 |
| Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients (NCT06635447) | AstraZeneca | 2024-09-26 |
| A Study in Patients With Myasthenia Gravis in China (NCT06700616) | AstraZeneca | 2024-09-26 |
| An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions (NCT06671405) | AstraZeneca | 2024-09-25 |
| A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA) (NCT06606847) | AstraZeneca | 2024-09-24 |
| A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. (NCT06542250) | AstraZeneca | 2024-09-18 |
| Chronicling the COPD Patient Journey and Change in COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF] (NCT06511193) | AstraZeneca | 2024-09-17 |
| Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma (NCT06563102) | AstraZeneca | 2024-09-11 |
| Real-world Study Assessing Efficacy of TezepeLumaB in Patients With Severe Asthma Regardless of Phenotype in Russia (NCT06566885) | AstraZeneca | 2024-09-10 |
| Clinical and Demographic Features of Patients With Moderate to Severe Active Systemic Lupus Erythematosus in Russia (NCT06759519) | AstraZeneca | 2024-08-30 |
| A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations (NCT06529419) | AstraZeneca | 2024-08-30 |
| Phase IIa Study Evaluating AZD7798 in Crohn's Disease (NCT06450197) | AstraZeneca | 2024-08-28 |
| A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants (NCT06547164) | AstraZeneca | 2024-08-27 |
| Volrustomig Priming Regimens Exploratory Phase II Platform Study (NCT06448754) | AstraZeneca | 2024-08-27 |
| A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease (NCT06610526) | AstraZeneca | 2024-08-23 |
| Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors (NCT06535607) | AstraZeneca | 2024-08-22 |
| Phase I PK Study of Budesonide/Albuterol Delivered From PT027 in Healthy Chinese Participants. (NCT06514157) | AstraZeneca | 2024-08-19 |
| A Study to Investigate Multiple Ascending Doses and Relative Bioavailability of AZD5004 in Healthy Participants (NCT06555822) | AstraZeneca | 2024-08-15 |
| EXACERBATIONS AND REAL-WORLD OUTOMES AMONG PATIENTS WITH COPD INITIATING BREZTRI (EROS+CP Japan Study) (NCT07103642) | AstraZeneca | 2024-08-15 |
| Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer (NCT06467357) | AstraZeneca | 2024-08-12 |
| Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780 (NCT06576765) | AstraZeneca | 2024-08-08 |
| A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients (NCT06549595) | AstraZeneca | 2024-08-07 |
| A Study to Investigate the Relative Bioavailability of AZD8630 Following a Device and Formulation Transition in Healthy Participants. (NCT06531811) | AstraZeneca | 2024-08-06 |
| A Study to Assess the PK, PD, Safety and Tolerability of Eplontersen in Healthy Chinese Volunteers (NCT06527755) | AstraZeneca | 2024-08-06 |
| Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma (NCT06435273) | AstraZeneca | 2024-08-05 |
| A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy Participants (NCT06554821) | AstraZeneca | 2024-08-05 |
| A Study of Andexanet Alfa in Patients Requiring Urgent Surgery or Procedure (NCT05926349) | AstraZeneca | 2024-08-02 |
| Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (NCT06380751) | AstraZeneca | 2024-08-01 |
| A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours (NCT06147037) | AstraZeneca | 2024-07-31 |
| REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER (NCT06826677) | AstraZeneca | 2024-07-30 |
| RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil (NCT06491862) | AstraZeneca | 2024-07-25 |
| A Non-interventional, Prospective Study With Benralizumab (NCT06422078) | AstraZeneca | 2024-07-25 |
| Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC (NCT06376084) | AstraZeneca | 2024-07-23 |
| A Study to Assess the Pharmacokinetics of AZD6793 When Administered Alone and in Combination With Itraconazole in Healthy Participants. (NCT06494644) | AstraZeneca | 2024-07-23 |
| A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma (NCT06502366) | AstraZeneca | 2024-07-22 |
| Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL (NCT05952024) | AstraZeneca | 2024-07-16 |
| Fasenra Pediatric Japan Post-Marketing Study(PMS) (NCT06427876) | AstraZeneca | 2024-07-16 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants (NCT06491550) | AstraZeneca | 2024-07-15 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled AZD4604 in Healthy Japanese and Chinese Participants. (NCT06519968) | AstraZeneca | 2024-07-15 |
| FAITH - Factor XA Inhibitor-Related InTracranial Haemorrhage (NCT06420011) | AstraZeneca | 2024-07-08 |
| Real-World Outcomes in COPD Patients Starting Trixeo (Budesonide/Glycopyrronium/Formoterol) in Spain. (NCT06321731) | AstraZeneca | 2024-07-02 |
| A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus (NCT06015737) | AstraZeneca | 2024-06-29 |
| NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations (NCT06494540) | AstraZeneca | 2024-06-28 |
| Clinical& Demographic Profiles of patIents With unControllEd Asthma in Russia: Multi-center oBsErvational ReGistry Study (NCT06521229) | AstraZeneca | 2024-06-27 |
| Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis (NCT06465810) | AstraZeneca | 2024-06-25 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults (NCT06469151) | AstraZeneca | 2024-06-24 |
| A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis) (NCT06455449) | AstraZeneca | 2024-06-20 |
| Observational Retrospective Study To Characterize and Assess Clinical Outcomes of Patients Receiving Tezepelumab in the Framework Of Use in Special Situations Prior to Commercialisation in Spain (NCT06487065) | AstraZeneca | 2024-06-17 |
| A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma (NCT06471257) | AstraZeneca | 2024-06-17 |
| Minimally Interventional Study on Prevalence of Emerging ESR1 Mutations in Liquid Biopsy in Three Cohorts of Patients With Breast Cancer in Comparison With Patient's Baseline ESR1 Mutation Status as Defined by Tissue Profiling. (NCT06417801) | AstraZeneca | 2024-06-17 |
| Real-World Treatment Study of Koselugo (Selumetinib) (NCT06360406) | AstraZeneca | 2024-06-15 |
| A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension (NCT06336356) | AstraZeneca | 2024-06-10 |
| Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR) (NCT06472310) | AstraZeneca | 2024-06-06 |
| A Translational Study for Prediction of Biomarkers and Identification of Phenotype and Endotype of COPD and Pre-COPD Outcomes in Chinese Population (NCT06724848) | AstraZeneca | 2024-06-05 |
| A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure (NCT06299826) | AstraZeneca | 2024-06-04 |
| EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study) (NCT06742736) | AstraZeneca | 2024-05-31 |
| Real-World Treatment Study of Soliris (Eculizumab) (NCT06448715) | AstraZeneca | 2024-05-28 |
| Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma (NCT06307665) | AstraZeneca | 2024-05-20 |
| A Study to Investigate the Safety and Pharmacokinetics of AZD6793 in Healthy Japanese and Chinese Participants (NCT06368440) | AstraZeneca | 2024-05-15 |
| UNFOLD Study Egypt (NCT06188494) | AstraZeneca | 2024-05-13 |
| Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care (NCT06422689) | AstraZeneca | 2024-05-10 |
| Long-Term Organ Damage: Anifrolumab Versus Real-World Standard of Care in Adult Patients With Active Systemic Lupus Erythematosus (NCT06485674) | AstraZeneca | 2024-05-09 |
| REACT - REAl Care for AsThma - A Disease Study to Identify Patients With Severe Uncontrolled Asthma (NCT06299306) | AstraZeneca | 2024-05-07 |
| Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone (NCT06388616) | AstraZeneca | 2024-05-02 |
| Change in Patient-repOrted Outcomes in COPD Patients Newly Initiated on TRIXEO AEROSPHERE in Real worlD (NCT06368427) | AstraZeneca | 2024-04-30 |
| A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer (NCT06297668) | AstraZeneca | 2024-04-29 |
| Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer (NCT06350097) | AstraZeneca | 2024-04-29 |
| Assessment of Safety of Olaparib in Chinese Patients With Ovarian Cancer in the Real-World Setting (NCT06324734) | AstraZeneca | 2024-04-29 |
| PRospectIve ObseRvatIonal mulTicenter Study of Patients With Arterial hYpertension and CKD in the Population of Russia (NCT06372431) | AstraZeneca | 2024-04-27 |
| Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany (NCT06336330) | AstraZeneca | 2024-04-25 |
| NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients (NCT06131424) | AstraZeneca | 2024-04-23 |
| Patient Characteristics, Treatment Patterns and Outcomes of Patients With Severe Asthma Treated With Tezepelumab in the Real World; a Retrospective, Observational Medical Chart Review Conducted in UK Severe Asthma Centres (NCT06455462) | AstraZeneca | 2024-04-22 |
| C.Difficile Observational Study (NCT06277999) | AstraZeneca | 2024-04-22 |
| To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations (NCT06194448) | AstraZeneca | 2024-04-21 |
| A Study to Investigate the Pharmacokinetics of Baxdrostat When Given Alone and in Combination With Itraconazole in Healthy Participants (NCT06357520) | AstraZeneca | 2024-04-16 |
| Brazilian Reality of Hepatocellular Carcinoma (NCT06230328) | AstraZeneca | 2024-04-15 |
| A Positron-emission Tomography Study to Determine Brain Exposure of [11C]Savolitinib in Healthy Volunteers (NCT06348355) | AstraZeneca | 2024-04-12 |
| Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function (NCT06307652) | AstraZeneca | 2024-04-12 |
| Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (NCT06357533) | AstraZeneca | 2024-04-11 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants (NCT06311760) | AstraZeneca | 2024-04-09 |
| A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers (NCT06304961) | AstraZeneca | 2024-04-08 |
| A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension (NCT06344104) | AstraZeneca | 2024-04-08 |
| A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants. (NCT06381466) | AstraZeneca | 2024-04-01 |
| A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. (NCT06268873) | AstraZeneca | 2024-03-29 |
| Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors (NCT06218914) | AstraZeneca | 2024-03-22 |
| A Study To Evaluate The Treatment Pattern Of Moderate-to-Severe Asthma Patients In China (NCT06422663) | AstraZeneca | 2024-03-22 |